Medicine
 |
|
2 june 2020 15:31:51 |
| Changes in REVEAL risk score in patients with pulmonary arterial hypertension treated with macitentan in clinical practice: results from the PRACMA study (BMC Pulmonary Medicine) |
|
Tweet Macitentan is a dual endothelin receptor antagonist indicated for the long-term treatment of pulmonary arterial hypertension (PAH). We evaluated the change over time in REVEAL risk score in incident and preval... |
| 287 viewsCategory: Medicine |
 Quality of care in prevention, detection and management of postpartum hemorrhage in hospitals in Afghanistan: an observational assessment (BMC Health Services Research)Anesthesia management in neonatal congenital bronchobiliary fistula: case report and literature review (BMC Anesthesiology) 
|
| blog comments powered by Disqus |
MyJournals.org
The latest issues of all your favorite science journals on one page
The latest issues of all your favorite science journals on one page
